News and articles

After months of collaboration and technical preparation, iQHT has successfully migrated iQemo from UKFast to Microsoft Azure. This marks a major milestone in improving performance, resilience, and scalability across all supported NHS sites and private healthcare providers. This was made possible through the dedicated efforts of their clinical and technical teams alongside our own. Together we laid the foundation for future innovation.

iQ HealthTech has been awarded a Bronze medal by EcoVadis, placing the company in the top 35% of assessed businesses worldwide. This recognition reflects our commitment to responsible practices across ethics, people, and sustainability, and marks a positive step forward in our ESG journey.

The BOPA TALLman recommendations are a key step in standardising Tall Man lettering for SACT drugs in the UK. IQ HealthTech supports this and is committed to helping customers implement it in line with BOPA and ISMP standards. To ensure safety benefits are fully realised, consistent adoption across all clinical systems and suppliers is essential.

Drug shortages have become a more common occurrence across the healthcare sector, negatively impacting the care delivered to patients and increasing stress amongst healthcare professionals. Shortages are influenced by many factors, from global events (e.g. COVID-19, Russia-Ukraine war) to financial and economical, increasing the cost of the drug and limiting the manufacture (e.g. cost of raw materials and energy to produce the drugs) (1). As a result, drug supply issues are often sudden and require immediate alternatives to be made available. This article aims to provide users with some helpful suggestions for how to manage a drug shortage within iQemo. (1) The Pharmaceutical Journal, PJ, June 2023, Vol 310, No 7974; 310(7974): :DOI:10.1211/ PJ.2023.1.189330

We are very pleased to report the next successful iQemo activation within SA Health at Lyell McEwin Hospital, Adelaide, South Australia

iQHealthTech in collaboration with Altera Digital Health in Australia have celebrated the successful go-live of iQemo at Mount Gambier and Districts Health Service!

Biosimilar switching is becoming more common as Rituximab, Trastuzumab and Bevacizumab all have biosimilars on the market. Due to stock shortages and contract prices, there may be a need to switch biosimilars more regularly. This will become more common as additional biosimilar products come to the market. iQemo can facilitate biosimilar switching through several mechanisms.